Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX11 vs EU-Perjeta in neoadjuvant HER2-positive HR-negative breast cancer
2022-002189-34Phase 3Terminated
- Sponsor
- Henlius
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pertuzumab in breast cancer (2 arms), sponsored by Henlius. Primary endpoint: Total pathological complete response rate assessed by IRC. Started Jul 2022; status: terminated.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-002189-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002189-34.